What we're reading, January 23, 2017: it is currently unclear what the impact President Donald Trump's executive order will have on the Affordable Care Act; New York requires that insurers cover birth control and abortions; and hospitals reexamine guidelines for opioid prescribing.
On day 1 in the White House, President Donald J. Trump signed an executive order impacting how the Affordable Care Act (ACA) is implemented. However, the order’s effect on the health law is unclear, and experts spent the weekend trying to decode it, reported The Wall Street Journal. The order may indicate that the new administration will stop enforcing the individual mandate, but no official statement has been made yet. Nevertheless, the order cannot repeal the ACA or do away with funding for coverage—only Congress has the power to do that.
New York State is taking measures to ensure women have access to contraception even if the ACA is repealed. According to Bloomberg, Governor Andrew Cuomo has ordered health insurers to cover birth control and medically necessary abortions in the event that a repeal is signed into law. Since insurance is regulated at both the federal and state levels, states may preserve parts of the ACA and continue to enforce provisions even if the federal government repeals the health law.
In the wake of the opioid epidemic, hospitals are reexamining guidelines for prescribing opioids in the emergency department (ED). STAT reported that hospitals are retraining ED doctors to minimize opioid prescriptions. At UK Healthcare, opioids are now only prescribed as a last resort, and St. Joseph’s Regional Medical Center in New Jersey is replacing opiods with less-addictive drugs and has a harpist playing music in the hallways of the ED. While these changes may prevent new addicts, they do not always address people who are already chronic opioid users.
Unmet Needs Remain in Secondary AML Following Treatment With HMAs
January 18th 2025The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated with hypomethylating agents (HMAs) for myeloid neoplasms such as myelodysplastic syndromes.
Read More
High HSP60 Expression Signals Poor Prognosis, Aggressive Tumors in Ovarian Cancer
January 16th 2025High heat shock protein 60 (HSP60) expression in patients with ovarian cancer is associated with larger tumors, advanced stages, and worse survival outcomes, highlighting its potential as a prognostic biomarker.
Read More